UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Annals of oncology, 2024-01, Vol.35 (1), p.107-117

2024

Volltextzugriff (PDF)

208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations

Annals of oncology, 2023-11, Vol.34, p.S1556

2023

Volltextzugriff (PDF)

2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study

Annals of oncology, 2023-10, Vol.34, p.S1201-S1201

2023

Volltextzugriff (PDF)

2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)

Annals of oncology, 2023-10, Vol.34, p.S1199-S1199

2023

Volltextzugriff (PDF)

883PAndrogen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Annals of oncology, 2019-10, Vol.30, p.v347-v348

2019

Volltextzugriff (PDF)

883P - Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Annals of oncology, 2019-10, Vol.30, p.v347-v348

2019

Volltextzugriff (PDF)

851PDPatient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

851PD - Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Annals of oncology, 2019-10, Vol.30, p.v330-v331

2019

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Annals of oncology, 2019-10, Vol.30, p.v330-v331

2019

Volltextzugriff (PDF)

A randomized, open-label, multicenter study evaluating thrombovascular events (TVEs) in subjects with cancer receiving chemotherapy and administered epoetin alfa (EPO) once weekly (QW) or three times a week (TIW) for the treatment of anemia

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19550-e19550

2010

Volltextzugriff (PDF)

Pregnancy interruption after second trimester diagnosis of fetal structural anomalies: The New Jersey Fetal Abnormalities Registry

American journal of obstetrics and gynecology, 2005-10, Vol.193 (4), p.1492-1497

2005

Volltextzugriff (PDF)

Genetic Effect of Two APOA Repeat Polymorphisms (Kringle 4 and Pentanucleotide Repeats) on Plasma Lp(a) Levels in American Samoans

Human biology, 2001-02, Vol.73 (1), p.91-104

2001

Volltextzugriff (PDF)

Genetic syndromes and genetic tests in colorectal cancer

Seminars in gastrointestinal disease, 2000-10, Vol.11 (4), p.207

2000

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

European urology supplements : official journal of the European Association of Urology, 2019-11, Vol.18 (11), p.e3413-e3414

2019

Volltextzugriff (PDF)

O6 - Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

European urology supplements : official journal of the European Association of Urology, 2019-11, Vol.18 (11), p.e3413-e3414

2019

Volltextzugriff (PDF)

Executive function performance and trauma exposure in a community sample of children

Child abuse & neglect, 2009-06, Vol.33 (6), p.353-361

2009

Volltextzugriff (PDF)

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

The New England journal of medicine, 2019-07, Vol.381 (1), p.13-24

2019

Volltextzugriff (PDF)

Self-Assembled Large Au Nanoparticle Arrays with Regular Hot Spots for SERS

Small (Weinheim an der Bergstrasse, Germany), 2011-08, Vol.7 (16), p.2365-2371

2011

Volltextzugriff (PDF)

Plasmonic Amplifiers: Engineering Giant Light Enhancements by Tuning Resonances in Multiscale Plasmonic Nanostructures

Small (Weinheim an der Bergstrasse, Germany), 2013-06, Vol.9 (11), p.1939-1946

2013

Volltextzugriff (PDF)

Solvent-Mediated End-to-End Assembly of Gold Nanorods

The journal of physical chemistry letters, 2010-09, Vol.1 (18), p.2692-2698

2010

Volltextzugriff (PDF)

Fast-forwarding quantum simulation with real-time quantum Krylov subspace algorithms

Physical review. A, 2022-10, Vol.106 (4), Article 042409

2022

Volltextzugriff (PDF)

Emergence of excited-state plasmon modes in linear hydrogen chains from time-dependent quantum mechanical methods

Physical review letters, 2011-11, Vol.107 (19), p.196806-196806, Article 196806

2011

Volltextzugriff (PDF)

Emergence of californium as the second transitional element in the actinide series

Nature communications, 2015-04, Vol.6 (1), p.6827-6827, Article 6827

2015

Volltextzugriff (PDF)

A randomized-control trial testing the impact of a multidisciplinary team response to older adult maltreatment

Journal of elder abuse & neglect, 2019-10, Vol.31 (4-5), p.307-324

2019

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(41)
Bücher
(1)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Humans
(11)
Life Sciences & Biomedicine
(9)
Male
(6)
Physical Sciences
(6)
Science & Technology - Other Topics
(6)
Chemistry
(5)
Female
(5)
Physics
(5)
Adult
(4)
Biological And Medical Sciences
(4)
Medical Sciences
(4)
Psychology
(4)
Trauma
(4)
Aged
(3)
Chemistry, Multidisciplinary
(3)
Chemistry, Physical
(3)
Materials Science
(3)
Materials Science, Multidisciplinary
(3)
Middle Aged
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

208O Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations

2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study

2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)

883PAndrogen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

883P - Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

851PDPatient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

851PD - Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

A randomized, open-label, multicenter study evaluating thrombovascular events (TVEs) in subjects with cancer receiving chemotherapy and administered epoetin alfa (EPO) once weekly (QW) or three times a week (TIW) for the treatment of anemia

Pregnancy interruption after second trimester diagnosis of fetal structural anomalies: The New Jersey Fetal Abnormalities Registry

Genetic Effect of Two APOA Repeat Polymorphisms (Kringle 4 and Pentanucleotide Repeats) on Plasma Lp(a) Levels in American Samoans

Genetic syndromes and genetic tests in colorectal cancer

Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

O6 - Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Executive function performance and trauma exposure in a community sample of children

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Self-Assembled Large Au Nanoparticle Arrays with Regular Hot Spots for SERS

Plasmonic Amplifiers: Engineering Giant Light Enhancements by Tuning Resonances in Multiscale Plasmonic Nanostructures

Solvent-Mediated End-to-End Assembly of Gold Nanorods

Fast-forwarding quantum simulation with real-time quantum Krylov subspace algorithms

Emergence of excited-state plasmon modes in linear hydrogen chains from time-dependent quantum mechanical methods

Emergence of californium as the second transitional element in the actinide series

A randomized-control trial testing the impact of a multidisciplinary team response to older adult maltreatment

Suchergebnisse filtern